Podcasts about Genoa

Mariah is out on bail… and Abby explodes!; Tessa comes face to face with Mariah; Nick’s drug addiction; Sharon and Noah are catching on; Billy and Sally Breakup; The Death of Delia Abbott: This Week’s Retro Report; Victoria vs. Billy and Phyllis, Plus Cane Recruits Daniel; and Claire breaks up with Holden! Visit https://www.yrchat.com to […]

Victor kidnapped Jack?! Nikki and Diane face off in the GCAC ladies room; Victoria and Nate kiss; Phyllis vs The World: Daniel, Sharon, Lauren; Nick takes drugs as Matt sends texts; The Noah/Audra/Kyle triangle that needs to happen; and Sally versus Chelsea! Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and […]

In this episode of BOAT Briefing, online editor Holly Margerrison is joined by travel and charter editor Georgia Boscawen to explore two very different sides of the superyacht world. After cruising the Society Islands on board 48-metre Oceanfast yacht Big Sky, Holly shares a first-hand account of navigating French Polynesia by yacht – from the dramatic peaks of Moorea and encounters with humpback whales to the practical realities of reaching and chartering in one of the most remote destinations on earth. The pair discuss how it compares to expedition hotspots such as Antarctica and the Galápagos, and whether the South Pacific truly lives up to its “trip of a lifetime” reputation. The conversation then shifts to the state of the market, where the pair break down five of the biggest stories shaping 2026 so far.This episode of BOAT Briefing is sponsored by Amico & Co, a Genoa-based, family-owned refit yard with more than 200 years of maritime heritage, renowned for its full-service refit expertise on large yachts, delivered through highly specialised in-house teams.Stories discussed:Palm Beach debutshttps://www.boatinternational.com/yachts/news/yachts-palm-beach-international-boat-show-2026Lürssen 109m O3 on sea trialshttps://www.boatinternational.com/yachts/news/lurssen-superyacht-project-shackleton-icecap-o3-sea-t…Oceanco 93m Draak becomes support vessel for 111m Leviathanhttps://www.boatinternational.com/yachts/news/draak-ex-tranquility-yacht-oceanco-rebuild-leviathanAbeking & Rasmussen confirms 100m+ new buildhttps://www.boatinternational.com/yachts/news/abeking-and-rasmussen-100m-plus-new-build-superyachtTurquoise Yachts launches 88m flagshiphttps://www.boatinternational.com/yachts/news/turquoise-yachts-flagship-superyacht-vento-angelique-…Benetti double launch: B.Now 67M hybrid yachtshttps://www.boatinternational.com/yachts/news/benetti-hybrid-bnow-67-two-superyacht-launchesBOATPro: https://boatint.com/3qwSubscribe: https://boatint.com/3qxContact us: podcast@boatinternationalmedia.com

In attesa di conoscere quando si giocherà la prossima gara casalinga contro la Roma, sabato prossimo i rossoblù faranno visita all'Inter. Che Genoa e che partita bisogna attendersi? Quali sono le ultime indicazioni dall'allenamento odierno? Ne parliamo qui. Buoncalcioatutti!

Join Alastair Stevenson and Michael Mervyn-Jones for a round-up of the main highlights from this month's SSY Monthly Shipping Review (MSR) alongside the latest news impacting shipping markets. The SSY Monthly Shipping Review is available to download for all SSY Navigator subscribers. To subscribe to SSY Navigator, simply email navigator@ssyglobal.com Panellist contact details Alastair StevensonHead of Digital Analysis, SSYE: a.stevenson@ssyglobal.comMichael Mervyn-JonesDirector of Communications and Marketing, SSYE: m.mervyn-jones@ssyglobal.com About SSY Established in 1880, SSY has grown to become one of the biggest and most trusted names in broking, operating around the world via its 28 local offices – with over 650 experts covering a range of major markets including Dry Cargo, Tankers, Derivatives, LNG, Sale and Purchase, Offshore, Rigs, Nuclear Energy, Chemicals, Aquaculture, LPG, Towage, Recycling and Corporate Finance. SSY has a global reach with offices in Aberdeen, Athens, Bergen, Copenhagen, Dubai, Geneva, Genoa, Hamburg, Hong Kong, Houston, Kristiansand, London, Madrid, Mumbai, New York, Osaka, Oslo, Rio, Rotterdam, Seoul, Shanghai, Singapore, Stamford-USA, Sydney, Tokyo, Vancouver, Varna, Zug.www.ssyglobal.com Hosted on Acast. See acast.com/privacy for more information.

Jake is back this week to give you another breakdown of the dramatic & disappointing to some Matchday 26 of the 2025/2026 Serie A Season!TIMESTAMPS:00:00-06:02 Intro & Goal OTW06:02-12:54 Lecce 0-2 Inter12:54-25.30 Milan 0-1 Parma (incl. Managerial Tension)25:30-31:18 Juve 0-2 Como31:18-41:48 Atalanta 2-1 Napoli41:48-48:59 Roma 3-0 Cremonese48:59-55:41 Cagliari 0-0 Lazio 55:41-01:03:31 Fiorentina 1-0 Pisa 01:03:31-01:14:28 Genoa 3-0 Torino01:14:28-01:21:35 Sassuolo 3-0 Verona 01:21:35-01:26:46 Bologna 1-0 Udinese01:26:46-01:34:56 Patron Corner (Tyson on Parma & Cuesta)01:34:56-01:39:28 Patron Fantasy League UpdateBecome a patreon: ⁦https://patreon.com/Serieaspotlight?⁩Special Shoutout to our Media Partners Benevo Bid - Check out their collection here; ⁦https://benevobid.com/⁩#acmilan #inter #juventus #torino #napoli #atalanta #bologna #fiorentina #roma #lazio #lecce #cagliari #udinese #monza #venezia #como #hellasverona #parma #empoli #genoa #football #soccer #footballpodcast #podcast PatreonYoutube: ⁦https://www.youtube.com/@serieaspotlight⁩Instagram: ⁦https://www.instagram.com/serieaspotlight/⁩Twitter: ⁦https://x.com/SerieASpotlight?

Serie A Gameweek 26 Review & Champions League Comeback Preview | Anglo Italian Podcast The Anglo Italian Podcast breaks down a dramatic Serie A Gameweek 26 (2025/26) featuring managerial sackings, title-race twists, and tightening European battles — before previewing a crucial week of Champions League action for Italian clubs. Torino sack Barone after a directionless campaign ends with a heavy 3–0 defeat in Genoa. Could Torino now find themselves dragged into a relegation battle? Juventus lose at home to Como, intensifying speculation around their manager's future. Do Juve need stability and patience, or is change inevitable? Napoli drop points at the top, losing 2–1 to Atalanta after a comeback inspired by Palladino's side. Napoli suddenly looking over their shoulders in the title race? Milan stunned at home by Parma, an odd and disappointing performance at San Siro. Does Carlos Cuesta deserve more credit for Parma's impressive season? Roma cruise past Cremonese 3–0, tightening the race for European qualification and building serious momentum. All Italian clubs face must-win second legs after poor away performances. Can Inter, Juventus, Napoli, and Atalanta stage dramatic European comebacks? Tactical adjustments, rotation dilemmas, and pressure moments ahead of decisive UCL nights. From Scudetto tension and relegation fears to Champions League survival, this episode covers everything shaping the Serie A 2025/26 season.

Il ministero delle Infrastrutture e dei Trasporti dovrebbe occuparsi del Paese e, invece, fa il tifo.  Fonti: video “La voce del tifoso: Rigore di Pogba in Genoa 0-2 Juventus del 20/09/15” pubblicato sul canale Youtube Mundialsport.it il 23 settembre 2015; video “Salvini: "Polemizzare sul caso Rogoredo è scorretto"” pubblicato sul canale Youtube alanews il 29 gennaio 2026; video “SALVINI: “RITORNO AL VIMINALE? SAREBBE BELLO..."” pubblicato sul canale Youtube Onemedia il 22 dicembre 2024; video “Una straordinaria Giorgia Meloni a Dritto e Rovescio intervistata da Paolo Del Debbio” pubblicato sul canale Youtube Giorgia Meloni News il 5 febbraio 2026; estratto dalla puntata del programma “Fuori dal coro” dell'1 febbraio 2026, disponibile sul sito mediasetinfinity.mediaset.it; account X gigi, 23 febbraio 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices

Giorno di riposo accordato da mister De Rossi al Genoa, con la ripresa fissata per domani al centro sportivo “Signorini”. Attesa per conoscere meglio le condizioni di Norton-Cuffy e Otoa. Buoncalcioatutti!

From Juventus in full crisis after Como loss who are REALLY pushing for top 4, Roma pushing Napoli for third spot who are fuming after refereeing controversy, Atalanta right back in top 4 race, Cremonese in trouble, to Inter Milan kill Scudetto race allowing focus on Coppa Italia, Torino and Genoa could be drawn into Serie B relegation race, and preview of Champions League, Europa League and Conference League leg 2 playoffs, as well as this week's Baggio, Serie ASS and Premface of the week plus much, much more when Nima and Carlo break down all the main talking points from Match Day 25 of the 2025/2026 Serie A season. Timestamps: 00:00 Intro - Match Day 26 Episode Overview 02:10 Juventus - Full Crisis Against Backdrop Of French Montana Performance 28:35 Como - Outstanding Result & Will Play In Europe Next Seasom 30:22 Roma - Gasperini Puts Club In Pole Position To Finish Top 4 & Pushing For Third 35:49 Cremonese - Davide Nicola MUST Be Sacked Or Else Serie B A Certainty 37:40 Napoli - Refereeing Controversy Costly As Hojlund & Manna Furious 49:49 Atalanta - Palladino Substitutions Of Scamacca & Samardzic Changes Game 56:17 Inter - +10 Advantage Means Chivu Can Focus On Coppa Italia & Champions League 01:05:25 AC Milan - Out Of Scudetto Race After Arteta & Arsenal NBA Block On Maignan 01:23:42 Best Of The Rest - Sassuolo Beat Hellas Destined For Serie B, Baroni Risk Torino Sack & Genoa Win But Still In Relegation Race 01:24:31 Champions League, Europa League & Conference League Playoff Leg 2 Preview - Juve Hope For Miracle Against Galatasaray, Atalanta Must Be Brave Against BVB, Inter Have To Manage Game Against Bodö/Glimt, Advantage Bologna Vs Brann & Fiorentina Cannot Fumble 3 Goal Lead Over Jagiellonia Białystok 01:27:52 Baggio, Premface & Serie ASS Of The Week - Osasuna Coach Alessio Lisci Beats Real Madrid, Gianluigi Donnarumma Heroics For Man City, Theo Walcott Epic Premfacery, Italian Journalist Racism Accusation On Bastoni & More If you want to support The Italian Football Podcast and get every episode, simply become a member on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon.com/TIFP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ OR ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ OR ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Memberships⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Your support makes The Italian Football Podcast possible.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok Learn more about your ad choices. Visit podcastchoices.com/adchoices

Centrocampisti del Milan difficili da pronunciare e giocatori del Torino che devono mangiare meglio.Vox 2 Box è un podcast dell'universo V2B Media.

Il commento alla vittoria per 3-0 del Genoa contro il Torino, che porta i rossoblù ad agganciare e superare i granata in classifica a quota 27 punti. Ripercorriamo la sfida in questa puntata. Buoncalcioatutti!

A oltre due terzi del cammino, 26esima giornata, il massimo campionato di calcio ha trovato ufficialmente un padrone: l'Inter. La vittoria nerazzurra di sabato a Lecce e la contemporanea caduta interna domenicale del Milan contro il Parma, lancia la squadra allenata da Chivu a +10 sui cugini rossoneri.

Novità in casa Torino: esonerato nel tardo pomeriggio Marco Baroni e panchina affidata a Roberto D'Aversa. Ne parlano in questo episodio Enrico Zambruno e Roberto Ugliono.Potrero, dove tutto ha inizio. Un podcast sul calcio italiano e internazionale.Su Como TV (https://tv.comofootball.com) nel 2026 potete seguire in diretta le partite della Saudi Pro League, Saudi King's Cup, Supercoppa d'Arabia, Copa Libertadores, Copa Sudamericana, Recopa, Liga Profesional Argentina, Trofeo de Campeones argentino, Eredivisie, Coppa di Francia, Scottish Premiership, Coppa di Scozia, Scottish League Cup, Scottish Championship, Coppa di Portogallo, Supercoppa di Portogallo, HNL croata e tutti i contenuti di calcio italiano e internazionale on demand.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/potrero--5761582/support.

Peter looks back on his trip to watch Torino's 2-1 defeat against Bologna in an eerie Stadio Grande Torino with many fans in the stadium choosing to stay away in a continued strike against owner Urbano Cairo. Sunday's match against Genoa is previewed in what could be a key game as both sides look to steer clear of being involved in a relegation battle. Hosted on Acast. See acast.com/privacy for more information.

Steve Wyss, James Eastham and Dan Roebuck preview the top weekend soccer matches across Europe and provide expert betting anaylsis on the change in odds, best bets and value plays. The podcast dives into Serie A's recent struggles in the Champions League, focusing on performances by Inter, Juventus, and Atalanta. Hosts discuss potential reasons behind these challenges. 00:00 Introduction 04:45 Genoa vs. Torino 09:30 Getafe vs. Sevilla 17:45 Atalanta vs. Napoli 20:35 Koln vs. Hoffenheim 25:00 Nantes vs. Le Havre 30:20 Angers vs. Lille 36:55 Strasbourg vs. Lyon 40:45 Toulouse vs. Paris FC 43:20 PSG vs. Metz

A due giorni dalla sfida tra Genoa e Torino, nel giorno in cui ha parlato anche Baldanzi in un'intervista esclusiva, le parole di De Rossi suonano come una carica in vista di domenica. Ne parliamo in questa puntata. Buoncalcioatutti!

In this very short episode, Giovanni Battista Martini, head of the Florence Henri Archive in Genoa, and the Italian art historians Paola Rosina and Roberto Lacarbonara will describe their favourite photo by Florence Henri in more detail for you. Please look out for the images on your smartphone or tablet while listening. As always, I added the photos to the chapters.

Il Genoa riprenderà domani ad allenarsi e lo farà a porte aperte, col centro sportivo "Signorini" che accoglierà i tifosi. Vediamo come si ripresenta la squadra di mister De Rossi alla settimana che porterà alla importante sfida col Torino. Buoncalcioatutti!

Dom is rescued and Mariah is captured; Tessa learns Mariah has been caught; Phyllis chloroforms Cane and gives Chancellor to Billy; Billy gives Newman Media to Sally; Diane blasts Jack over his relationship with Nikki; Patty Williams is returning, played by Stacy Haiduk; Claire and Holden hold hands, and Kyle and Audra kiss; Visit https://www.yrchat.com […]

This week on BOAT Briefing, travel and charter editor Georgia Boscawen sits down with Anna Nash, president of Explora Journeys, to discuss how the brand is reshaping perceptions of ocean travel. Ahead of the delivery of Explora III, Nash reveals how Explora Journeys is redefining modern cruising and carving out its place in the ultra-luxury market. A relative newcomer that launched its first vessel in 2023, the brand is pursuing an ambitious expansion plan, with six ships on track for delivery by the end of 2028.This episode of BOAT Briefing is sponsored by Amico & Co, a Genoa-based, family-owned refit yard with more than 200 years of maritime heritage, renowned for its full-service refit expertise on large yachts, delivered through highly specialised in-house teams.BOATPro: https://boatint.com/3qwSubscribe: https://boatint.com/3qxContact us: podcast@boatinternationalmedia.com

Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in this population, the importance of PSA doubling time as a prognostic factor and with an emphasis on treatment de-escalation to limit toxicity and improve patient outcomes. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO authors Dr. David Einstein and Dr. Ravi Madan. Dr. Einstein is a medical oncologist specializing in genitourinary malignancy working at Beth Israel Deaconess Medical Center, part of the DFCI Cancer Center, and an assistant professor at Harvard Medical School. Dr. Madan is a senior clinician at the National Cancer Institute (NCI), where he focuses on conducting clinical research in prostate cancer, particularly in the field of immunotherapy. Today, we will be discussing the article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." So, thank you for speaking with us, Dr. Einstein and Dr. Madan. David Einstein: Thanks for having us. This is a great pleasure. Ravi Madan: Appreciate being here. Davide Soldato: So, I just want to start from a very wide angle. And the main question is why did you feel that there was the need to convey a consensus and a working group to talk about this specific topic: biochemically recurrent prostate cancer? What has been the change in current clinical practice and in the trial design that we are seeing nowadays? And so, why was it necessary to convey such a consensus and provide considerations on novel clinical trials? David Einstein: Yeah, so I think it's very interesting, this disease state of biochemically recurrent prostate cancer. It's very different from other disease states in prostate cancer, and we felt that there was a real need to define those differences in clinical trials. Years ago, metastatic castration-resistant prostate cancer was the primary disease state that was explored, and over time, a lot of things shifted earlier to metastatic disease defined on a CAT scan and bone scan to an earlier disease state of metastatic castration-sensitive prostate cancer. And the clinical trial principles from late-stage could be applied to MCSPC as well. However, BCR is very different because the patients are very different. And for those reasons, there are unique considerations, especially in terms of toxicity and treatment intensity, that should be applied to biochemically recurrent prostate cancer as opposed to just using the principles that are used in other disease states. And for that reason, we thought it was very important to delineate some of these considerations in this paper with a group of experts. Davide Soldato: Thanks so much. So, one of the main changes that have been applied in recent years in clinical practice when looking at biochemically recurrent prostate cancer is the use of molecular imaging and particularly of PSMA PET. So, first of all, just a quick question: was the topic of the consensus related on which threshold of PSA to use to order a PET scan to evaluate this kind of patient? David Einstein: Yeah, thanks for that question. It's a super important one. The brief answer is that no, we did not address questions about exactly when clinicians would decide to order scans. We were more concerned with the results of those scans in how you define different disease states. But I think as a broader question, I think a lot of folks feel that finding things on a scan equates that with what we used to find on conventional scans. And fundamentally, we actually sought to redefine that disease space as something that's not equivalent to metastatic disease, and rather coined the term "PSMA-positive BCR" to indicate that traditional BCR prognostic criteria and factors still apply, and that these patients have a distinct natural history from those with more advanced metastatic disease. Ravi Madan: And if I may just add that the National Cancer Institute is running a trial where we're prospectively monitoring PSMA-positive BCR patients. And that data is clearly showing that, much like what we knew about BCR a decade ago, PSMA findings in BCR patients do not change the fact that overall, BCR is an indolent disease state. And the findings, which are usually comprised of five- to seven-millimeter lymph nodes, do not endanger patients or require immediate therapy. And so, while PSMA is a tool that we can be using in this disease state, it doesn't really change the principal approach to how we should manage these patients. And as Dr. Einstein alluded to, there is a drive to create a false equivalency between PSMA-positive BCR and metastatic castration-sensitive prostate cancer, but that is not supported by the data we're accumulating or any of the clinical data as it exists. Davide Soldato: One thing that it's very important and you mentioned in your answer to my question was actually the role of PET scan and conventional imaging, so CAT scan and bone scan that we have used for years to stage patients with metastatic prostate cancer. And you mentioned that there is a distinction among patients who have a positive PET scan and a BCR, and patients who have a positive conventional imaging. And yet, we know that sometimes the findings of the PET scan are not always so clear to interpret. So, I just wanted to understand if the consensus reached an agreement as to when to use conventional imaging to potentially resolve some findings that we have on PET scan among thess patients with BCR? David Einstein: Yeah, I think there's a number of questions actually buried within that question. One of which is: does PSMA PET result in false positives? And the answer has definitely been yes. There's a known issue with false-positive rib lesions. And so, first and foremost, we need to be very careful in calling what truly is suspicious disease and what might actually not be cancer or might be something that is totally separate. So I think that's the first part of the answer to that question. The second is to what extent do we need to use paired PET and conventional imaging to define this disease state? In other words, do you have to have positive findings on one and negative findings on the other in order to enter this definition? The challenge there, as we discussed, is that logistically, oftentimes it's hard to get patients to do multiple sets of scans to actually create that definition. Sometimes it's difficult to get insurers to pay for such scans. And finally, it's hard to sometimes blind radiologists to the results of one scan in reading the other. So, we did have some deliberations about to what extent you could use some of the CAT scan portion of a PSMA PET in order to at least partially define that. We also talked about using bone scans to confirm any bone findings seen on PET. But I think another important part of this is not just the baseline imaging, but also what's going to be done serially on a study in order to define responses and progression. And that's sort of a whole separate conversation about to what extent you can interpret changes in serial PET. Ravi Madan: And just to pick up on the key factor here, I think that the PSMA PET in BCR is pretty good at defining lymph node disease, and that's actually predominantly 80 to 90 percent of the disease seen on these findings. It might be pretty good at also defining other soft tissue findings. The real issues come to bone findings. And one thing the group did not feel was appropriate was to just define only PSMA-positive bone findings confirmed on a CT bone window. There's not really great data on that, but the working group felt that, when in the rare situation, because it is relatively rare, a PSMA-positive finding is in a bone, a bone scan should be done. And it's worth noting that Phu Tran, who is a co-author and a co-leader of this working group, his group has already defined that underlying genomics of conventionally based lesions, such as bone scan, are more aggressive than findings on next-gen imaging, such as PSMA. So, there is also a genomic underlying rationale for defining the difference between what is seen on a PET scan in a bone and what is seen on a bone scan. Davide Soldato: Coming back to this issue of PET PSMA sometimes identifying very small lesions where we don't see any kind of correlates on conventional imaging or where we see only very little alteration on the bone scan or in the CT scan, was there any role that was imagined, for example, for MRI to distinguish this type of findings on the PET scan? Ravi Madan: So, I think that, again, what can be identified on a PSMA frequently cannot be seen on conventional imaging. We didn't feel that it was a requirement to get an MRI or a CT to necessarily confirm the PSMA findings. I think that generally, we have to realize that in this disease state, that questionable lesions are going to be seen on any imaging, including PSMA. We've actually probably put way too much faith in PSMA findings thus far, as Dr. Einstein alluded to with some of the false positives we're seeing. So, I think that these false positives are going to have to be baked into trials. And in terms of clinical practice, it highlights the need to again, not overreact to everything we see and not necessarily need to biopsy everything and put patients' health in jeopardy to delineate a disease that's indolent anyway. Davide Soldato: Thanks so much. That was very clear. So, basically, the main driver was really also the data showing that if we have a BCR, so a patient with a biochemically recurrent disease that is positive on the conventional imaging, this is usually associated with a different aggressiveness of the disease. But coming back to a comment that you made before, Dr. Madan, you said that even if we talk about PSMA-positive BCR, we are still talking about BCR and the same criteria should apply. So, what we have used for years in this space to actually try to stratify the prognosis of patients is the PSA doubling time, so how quickly the PSA rises over time. So, coming back to that comment, was the consensus on the PSA doubling time basically retained as what we were using before, so defining patients with a doubling time less than 12 months, 10 months, 9 months, as patients with a higher risk of progressing in terms of developing metastatic disease? Ravi Madan: Yes, so that's a very important point. And the working group defined high-risk BCR as a PSA doubling time less than six months. And this really comes from Johns Hopkins historical data, which shows that if your doubling time is three months or less, there's about a 67 percent chance of metastasis at five years. If it's between three and six months, it's 50 percent. And if it's over six months, if it's between six and nine months, it's roughly only 27 percent. There are trials that are accruing with eligibility criteria that they may describe as high-risk that are beyond six months, but the data as really it's been defined in the literature highlights that truly high-risk BCR is less than six months. And the working group had a consensus on that opinion, and that was our recommendation. David Einstein: And I think an important follow-on to that is that's regardless of PET findings, right? And so, we present a couple of case studies of patients with positive PET findings who have a long doubling time, in whom the disease is in fact indolent, as you would have expected from a traditional BCR prognostic standpoint. Obviously, there are patients in whom they have fast doubling times, and even if they do not have PET findings, that doesn't make them not high-risk. Ravi Madan: And just to follow up that point, I will let you know a little bit of a free preview that my colleague Melissa Abel from the NCI will be presenting PSMA findings in the context of PSA doubling time at ASCO GU if that data is accepted. Davide Soldato: Looking forward for those data because I think that they're going to clarify a lot of the findings that we have in this specific population. And coming back to one of the points that we made before, so PET PSMA has a very high ability to discriminate also a very low burden of disease, which we currently refer to as oligometastatic biochemically recurrent prostate cancer, which is not entirely defined as an entity. But what we are seeing both in some clinical trials, which use mainly conventional imaging, but also what we're starting to see in clinical practice, is that frequently we use the metastasis-directed therapy to treat these patients. So, just a little bit of a comment on the use of this type of strategy in clinical practice and if the panel thought of including this as, for example, a stratification criteria or mandated in the design of novel clinical trials in the field of BCR? David Einstein: Yeah, I think that's an incredibly important point. You know, fundamentally, there's a lot of heterogeneity in practice where some folks are using local salvage approaches, some are using systemic therapies, in some cases surveillance may be reasonable, or some combination of these different strategies. We certainly have phase two data from multiple trials suggesting that met-directed therapy may help buy patients time off of treatment until subsequent treatments are started. And that in and of itself may be an important goal that we can come back to in discussing novel endpoints. I think what our panel acknowledged was that, in some sense, the clinical practice has gotten even farther ahead than where the data are, and this is being offered pretty routinely to patients in practice. And so, what became clear was that we, in developing clinical trials, cannot forbid investigators from doing something that would be within their usual standard of care, even if it might not be supported by the most robust data. But at minimum, it definitely should be used as a stratification factor, or in some trial designs, you can do met-directed therapy after a primary endpoint is assessed. And that offers a compromise between testing, say, the effect of a systemic therapy but also not excluding patients and investigators from doing what they would have done had they not been on a study. Ravi Madan: And I would just like to follow up your phrasing in the question of "oligometastatic prostate cancer." We have a figure in the paper and it highlights the fact that, unfortunately, that term in prostate cancer is imaging agnostic. And we've already discussed in this podcast, as well as in the paper, that imaging used to define a metastatic lesion, whether it's PSMA or conventional imaging, carries with it a different clinical weight and a different prognosis. So, we feel in the working group, that the correct term for this disease state of PSMA-positive BCR is just that: PSMA-positive BCR. We also have to realize that when we talk about oligometastatic disease, while it's imaging agnostic, it seems to be numerically based, whether it's five or three or 10 depending on the trial. But PSMA-positive BCR does not have a limit in terms of the number of lesions. And so again, we just feel that there is an important need to delineate what we're seeing in this disease state, which again is PSMA-positive BCR, and that should be differentiated frankly from oligometastatic disease defined on other imaging platforms. David Einstein: Right, and that also makes clear that patients can have polyfocal disease on PET that still is not what we would consider metastatic, but goes beyond the traditional definition of oligometastatic. So, in other words, just because someone has PET-detected disease only, that does not automatically equate with oligometastatic. Davide Soldato: Thanks so much. So, you were speaking a little bit, Dr. Einstein, about the different types of treatment that we can propose or not propose to this patient because you mentioned, for example, that in clinical practice MDT, so metastasis-directed therapy, is becoming more and more used. For these patients, we can potentially use systemic treatments, which include androgen deprivation therapy, which can be given continuously or in an intermittent fashion. And recently, we can also use novel systemic therapies, for example, enzalutamide, to treat this type of patient. So, given that the point of the consensus was really to provide consideration for novel clinical trials in this space, what was the opinion on the panel regarding the control arm? So, if we're looking at a novel therapy in the BCR space, does the control arm need to include a therapy or not? And if so, which therapy? David Einstein: Yeah, this is a super important question and one that's subject to a lot of discussion, especially in light of recent data from EMBARK. What we came to a consensus around was the fact that neither MDT nor systemic therapy should be required as a control arm on BCR trials. And we can talk about a number of reasons for that. There's also the pragmatics of what investigators might actually accrue patients to and what they would consider their standard of care, and that's important to factor in, too. I think that one of the major goals of our working group was outlining what kinds of trials we would like to see in the future and where the limitations of the current data stand. For example, EMBARK proposes a strategy of a single treatment discontinuation and resumption at a predefined threshold indefinitely. That's probably not how most people are practicing. Most folks are probably using some version of intermittent therapy as they would have before this trial, but we actually don't have any data supporting that. Moreover, we don't have data comparing different intermittent strategies to one another. We don't know what the right thresholds are, we don't know how much time we buy patients off treatment, and we don't know to what extent MDT modifies that. And so, those are all really important questions to be asking in future versions of these trials. I'd say my second point would be that a lot of drug development is happening with novel therapies that are not hormonal, trying to bring them into this space. And when you think about trying to compare one of those types of therapies to a hormonal therapy on short-term endpoints, the hormonal therapy is always going to win. Hormonal therapy is almost universally effective, it will bring down PSAs, and it will prolong, quote-unquote, "progression." The downside of that is that hormonal therapy doesn't actually modify the disease, it suppresses it, and it tends to have fairly transient effects once you remove it. And so, part of our goal was in trying to figure out some novel endpoints that would allow these novel types of therapies to be examined head-to-head against a more traditional type of hormonal therapy and have some measurement of some of the more long-term impacts. Davide Soldato: So, jumping right into the endpoints, because this is a very relevant and I think very well-constructed part of the paper that you published. Because in the past we have used some of these endpoints, for example, metastasis-free survival, as potentially a proxy for long-term outcomes. But is this the right endpoint to be using right now, especially considering that frequently this outcome is measured using conventional imaging, but we are including in these trials patients who are actually negative on conventional imaging but have a positive PSMA when they enter this type of trial? David Einstein: Yeah, there's a number of challenges with those types of endpoints. One of which is, as you say, we're changing the goalposts a little bit on how we're calling progression. We still don't exactly understand what progression on PET means, and so that's something that is challenging. That said, we're also cognizant of the fact that many times investigators are likely to get PET scans in the setting of rising PSA, and that's going to affect any endpoint that relies purely on conventional imaging. So, there's some tension there between these two different sets of goalposts. One thing that we emphasize is that not only are there some challenges in defining those, but also there're challenges in what matters to a patient. So, if a progression event occurs in the form of a single lesion on a PET scan or even a conventional image, that might be relevant for a clinical trial but might be less relevant for a patient. In other words, that's something that, in the real world, an investigator might use serial rounds of metastasis-directed therapy or intermittent therapy to treat in a way that doesn't have any clinical consequences for the patient necessarily. In other words, they're asymptomatic, it's not the equivalent of a metastatic castration-resistant disease progressing. And so, we also need to be cognizant of the fact that if we choose a single endpoint like PFS, that there's going to be many different versions of progression, some of which probably matter clinically more than others, and some of which are more salvageable by local therapies than others. Ravi Madan: So I think the working group really thoughtfully looked at the different options and underscored perhaps strengths and weaknesses, and I think that's presented as you mentioned in the paper. But I think it's also going to depend on the modality, the approach of the therapeutic intervention. In some cases if it's hormone-based, then maybe PSA is providing some early metrics, maybe metastasis-free survival is more relevant in a continuous therapy, but intermittent therapies might have a different approach. There's emerging immunotherapy strategies, radiopharmaceutical strategies, they might have some more novel strategies as well. I think we have to be open-minded here, but we also have to be very clear: we do not know what progression is on a PSMA scan. Just new lesions may not carry the clinical significance that we think, and we may not know what threshold that ultimately becomes clinically relevant is. So, I do think that there was some caution issued by the working group about using PSMA as an endpoint because we still do not have the data to understand what that modality is telling us. Again, I'm optimistic that the National Cancer Institute's prospective data set that we've been collecting, which has over 130 patients now, will provide some insights in the months and years ahead. Davide Soldato: So, just to ask the question very abruptly, what would you feel like the best endpoint for this type of trials is? I understand that is a little bit related to the type of treatments that we're going to use, whether it's intermittent, whether it's continuous, but do we have something that can encapsulate all of the discussion that we have up until this point? David Einstein: Yeah, so that's a perfect segue to the idea of novel endpoints, which we feel are very important to develop in these novel disease spaces. So, one thing that we discussed was an endpoint called treatment-free survival, which conceptually you can think of as exactly what it sounds like, but statistically you actually have to do some work to get there. And so essentially, you imagine a series of Kaplan-Meier curves overlaid: one about overall survival, one time to next therapy, one time on initial therapy. You can actually then take the area under those curves or between those curves and essentially sum it up using restricted mean survival time analysis. And that can give you a guide about the longitudinal experience of a patient: time spent on treatment versus off treatment; time spent with toxicity versus without toxicity. And importantly, each one of those time-to-event metrics can be adjusted depending on exactly what the protocol is and what is allowed or not allowed and what's prespecified as far as initiation of subsequent therapies. So, we felt that this was a really important endpoint to develop in this disease space because it can really capture that longitudinal aspect. It can really reward treatments that are effective in getting durable responses and getting patients off of therapy, because unfortunately, PFS-based endpoints generally reward more or longer systemic therapy versus shorter or no systemic therapy, and that's sort of an artificial bias in the way those endpoints are constructed. So, I think that there are challenges of course in implementing any new endpoint, and some of the things that are really critical are collecting data about toxicity and about subsequent therapies beyond what a typical trial might collect. But I think in this kind of disease space, that longitudinal aspect is critical because these are really patients who are going to be going through multiple rounds of therapy, going to be going on and off treatments, they're going to be using combinations of local and systemic therapies. And so, any one single endpoint is going to be limited, but I think that really highlights the limitations of using PFS-based endpoints in this space. Ravi Madan: I also think that in the concept of treatment-free survival lies one of the more powerful and, honestly, I was surprised by this, that it was so universally accepted, recommendations from the committee. And that was that the general approach to trials in this space should be a de-escalation of the EMBARK strategy as it's laid out with relatively continuous therapy with one pause. And so, I think again, buried in all of this highlights the need for novel endpoints like treatment-free survival. We get to the fact that these are patients who are not at near-term clinical risk from symptoms of their disease, so de-escalating therapies does not put them at risk. And if you look at, for example, lower-volume metastatic castration-sensitive prostate cancer, it's become realized that we need to de-escalate, and there are now trials being done to look at that. Historically, we know that BCR is an indolent disease process for the vast majority of patients who are not at near-term risk from clinical deterioration. So, therefore, we shouldn't wait a decade into abundant BCR trials to de-escalate. The de-escalation strategy should be from the outset. And that was something the committee really actually universally agreed on. David Einstein: And that de-escalation can really take multiple forms. That could be different strategies for intermittent therapy, different start-stop strategies. It could also mean actually intensifying in the short-term with the goal long-term de-intensification, kind of analogous to kidney cancer where we might use dual checkpoint inhibitors up front with some higher upfront toxicity but with the hope of actually long-term benefit and actually being able to come off treatment and stay in remission. Those kinds of trade-offs are the types of things that are challenging to talk about. There's not a one-size-fits-all answer for every patient. And so, that's why some of these endpoints like treatment-free survival would be really helpful in actually quantifying those trade-offs and allowing each patient to make decisions that are concordant with their own wishes. Davide Soldato: Thanks so much. That was very clear, especially on the part of de-escalation, because, as you were mentioning, I think that we are globally talking about a situation, a clinical situation, where the prognosis can be very good and patients can stay off treatment for a very long period of time without compromising long-term outcomes. And I think that well-constructed de-escalation trials, as you were mentioning and as the consensus endorsed, are really needed in this space also to limit toxicity. This brings us to the end of this episode. So, I would like to thank again Dr. Einstein and Dr. Madan for joining us today. David Einstein: We really appreciate the time and the thought, and I think that even starting these types of discussions is critical. Even just recognizing that this is a unique space is the beginning of the conversation. Ravi Madan: Yeah, and I want to thank JCO for giving us this forum and the opportunity to publish these results and all the expert prostate cancer investigators who were part of this committee. We produced some good thoughts for the future. Davide Soldato: We appreciate you sharing more on your JCO article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Matt and Jake are back this week to give you another breakdown of the dramatic & controversial Matchday 24 of the 2025/2026 Serie A Season!TIMESTAMPS: 00:00 – Intro + Matchday 24 overview00:42 – Goal of the Week nominees & debate 04:30 – Bologna vs Milan recap 09:17 – Sassuolo vs Inter recap 11:51 – Lautaro milestone & Inter dominance 20:50 – Inter vs Juventus preview26:20 – Napoli vs Genoa match breakdown 32:00 – Napoli tactics, red card & penalties 34:10 – Genoa players spotlight (Malinovskyi, Colombo, GK issues) 36:20 – Table update: Napoli, Genoa & relegation battle45:10 – Udinese vs Lecce recap 1:30:30 – Bologna struggles & striker issues 1:47:50 – Udinese inconsistency discussion 2:01:05 – Fiorentina late-game collapses & Torino notes2:16:55 – End segment intro (predictions, fantasy) 2:17:20 – Matchday 25 predictions 2:21:50 – Fantasy league update 2:25:20 – Fan voice note: Juventus season review 2:33:40 – Juve coaching situation & long-term outlook 2:35:00 – Outro / closing thoughtsBecome a patreon: ⁦https://patreon.com/Serieaspotlight?⁩Special Shoutout to our Media Partners Benevo Bid - Check out their collection here; ⁦https://benevobid.com/⁩#acmilan #inter #juventus #torino #napoli #atalanta #bologna #fiorentina #roma #lazio #lecce #cagliari #udinese #monza #venezia #como #hellasverona #parma #empoli #genoa #football #soccer #footballpodcast #podcast PatreonYoutube: ⁦https://www.youtube.com/@serieaspotlight⁩Instagram: ⁦https://www.instagram.com/serieaspotlight/⁩Twitter: ⁦https://x.com/SerieASpotlight?

From Dimarco assist hattrick as Inter pummel Sassuolo, Juventus drop important points in Champions League race, Lazio score wonderful Sarri ball goal, McTominay shines as Napoli win after Vergara penalty scandal, Colombo impresses as De Rossi's Genoa fuming with rage, to Lecce drag Cremonese into relegation battle with Udinese late winner when Fiorentina fail to beat Torino, as well as this week's Baggio, Serie ASS and Premface of the week plus much, much more when Nima and Carlo break down all the main talking points from Match Day 24 of the 2025/2026 Serie A season. Timestamps: 00:00 Intro - Match Day 24 Episode Overview 02:32 Inter Milan - Dimarco Serie A MVP Shouts As Lautaro Writes Club History 21:51 Juventus - Are Cambiaso & Di Gregorio Good Enough To Be At Juve? 41:45 Lazio - Isaksen Excellent Finish After A Vintage Sarri Ball Move 47:49 Napoli - McTominay Shines, Buongiorno Awful, In Vergara Penalty Scandal 01:08:16 Genoa - Colombo Continues To Score & Impress As De Rossi Fuming 01:10:09 Best Of The Rest - Pisa & Hellas Verona Both Lose In Goalless Draw, Fiorentina Fail To Beat Torino After Shambolic Defending, Lecce Record Fundamentally Important Win Over Udinese Drags Cremonese In The Relegation Race & Parma Beat Hapless Bologna 01:14:50 Baggio, Premface & Serie ASS Of The Week - Piers Morgan Arsenal Word Salad, Paddy McGuiness Ronaldinho Facepalm, Mariah Carey Winter Olympic Cringe "Singing" & More If you want to support The Italian Football Podcast and get every episode, simply become a member on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon.com/TIFP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ OR ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ OR ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Memberships⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Your support makes The Italian Football Podcast possible.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok Learn more about your ad choices. Visit podcastchoices.com/adchoices

Victor/Lily/Cane abduction ruse; Phyllis and Cane takeover Victor’s office; Sienna leaves Noah and Genoa City; Claire and Holden plan another trip to LA; Mariah calls herself Dom’s Mommy; Baby snatching retrospective with Sheila Carter; Abby, Devon, Sharon, Tessa, and Detective Burrows discuss Mariah’s motives. Visit https://www.yrchat.com to chat with fun and friendly fans of The […]

Iniziamo la puntata con Leo Turrini e con il nostro Dario Ricci per ripercorrere quanto successo nel primo giorno e mezzo delle Olimpiadi invernali di Milano-Cortina. Positivo l'esordio degli atleti italiani.A seguire parliamo di discesa libera femminile e del podio centrato da Sofia Goggia. Lo facciamo insieme a Daniela Merighetti, che ha commentato l'evento per Eurosport.Spazio anche alla domenica di Serie A: facciamo il punto sul campionato insieme a Xavier Jacobelli. Poi Franco Vanni ci porta a Reggio Emilia, dove tra pochi minuti inizierà la sfida tra Sassuolo e Inter.Stasera intanto andrà in campo anche la Juventus, pronta a ricevere la visita della Lazio dell'ex Sarri. Sentiamo cosa ne pensano Guido Vaciago e Dario Marcolin. Con Gianpaolo Calvarese invece torniamo sulla gara di ieri tra Genoa e Napoli e su qualche episodio arbitrale che merita di essere approfondito.C'è gloria anche per il rugby. La Nazionale di Quesada supera la Scozia con un bel 18-15 e centra la vittoria all'esordio del Sei Nazioni.In coda torniamo sulle Olimpiadi di Milano-Cortina per un ultimo aggiornamento con Guido Bagatta.

Join Dan Roebuck, Steve Wyss, and James Eastham discussing European football transfers, including Adrian Lado's move to Como, Wolfsburg's defensive signings, and Juventus' betting edge against Lazio. The betting experts make their picks and best bets for the Bundesliga, La Liga, Serie A and Ligue 1. 00:00 Transfer Talk 04:45 Juventus vs. Lazio 08:30 Sassuolo vs. Inter Milan 12:25 Genoa vs. Napoli 18:20 Rayo Vallecano vs. Rayo Oviedo 22:00 PSG vs. Marseille 26:55 Lens vs. Rennes 29:00 Brest vs. Lorient 32:40 Le Havre vs. Strasbourg 35:00 Angers vs. Toulouse 39:55 Freiburg vs. Werder Bremen 42:30 Bayern Munich vs. Hoffenheim 45:45 Atalanta vs. Cremonese

A review of a Hawaii cruise on Norwegian Cruise Line's Pride of America.  Richard has cruise news on:  Carnival Hikes Gratuities & Drink Package – Starting April 2, gratuities rise to $17/day in standard rooms and $19/day in suites. Bottomless Bubbles soda package also increases to $11.99/day. Trevi Fountain Adds Entry Fee – Visitors must now pay $2.40 to get close to Rome's iconic fountain; locals and kids under 6 exempt. Jazz Cruise Tragedy – Renowned jazz musician Ken Peplowski passed away onboard Celebrity Summit during the annual Jazz Cruise. Drug Bust at PortMiami – Five passengers arrested with narcotics before boarding Symphony of the Seas for a themed Atlantis cruise. MSC Guests Left Behind – MSC Orchestra couldn't dock in Marseille due to port protests, forcing guests to rejoin in Genoa. MSC Adding Yacht Club – MSC Musica and Orchestra will receive the Yacht Club luxury enclave during upcoming refurbishments. Disney Adventure Breaks Record – Becomes the largest passenger ship to transit the Panama Canal on its way to Singapore homeport. Sponsor Cruise line protection is designed to help if you can't take your cruise. Third-party travel insurance helps protect you during the trip. Including medical care, delays, and unexpected issues. Compare plans and save up to 30% at TripInsurance.com. About Cruise Radio: Cruise Radio has been delivering cruise news, ship reviews, and money-saving tips weekly since 2009.

https://thecommunists.org/2026/01/09/news/model-motion-dockers-dont-work-for-war/ Those loading cargo ships have a vital strategic place in the economy; we must use this power to stop the war machine. Dockers at the Italian port of Genoa have repeatedly highlighted the role of their port in the imperialist war machine. They have refused to load cargos that were meant for the wars in Ukraine and Palestine, and have led stoppages and general strikes in solidarity with Palestine. This example needs to be followed and the movement to become widespread. The war machine cannot function without the working class! Subscribe! Donate! Join us in building a bright future for humanity! www.thecommunists.org www.lalkar.org www.redyouth.org Telegram: t.me/thecommunists Twitter: twitter.com/cpgbml Soundcloud: @proletarianradio Rumble: rumble.com/c/theCommunists Odysee: odysee.com/@proletariantv:2 Facebook: www.facebook.com/cpgbml Online Shop: https://shop.thecommunists.org/ Education Program: https://thecommunists.org/education-programme/ Each one teach one! www.londonworker.org/education-programme/ Join the struggle www.thecommunists.org/join/ Donate: www.thecommunists.org/donate/

A story of brotherhood, defiance, and silence.For 37 years, Napoli and Genoa shared one of calcio's most unlikely bonds - a gemellaggio born against power, and lost to time.

In this episode, we speak with Dr. Jayne MacMahon about an international collaborative study in juvenile dermatomyositis (JDM) involving pediatric rheumatology centers in Genoa, Italy, and Toronto, Canada. She discusses the study's motivation, key disease activity measures, treatment targets, and definitions of remission, along with major findings on time to remission, steroid exposure, and treatment outcomes across cohorts. Dr. MacMahon also reflects on the study's limitations, future research directions, her career path in pediatric rheumatology, and how international collaboration can shape the future of care for children with autoimmune diseases.  Toward a Treat-to-Target Strategy in Juvenile Dermatomyositis: What Are the Suitable Targets and Optimal Timing of Their Achievement?   

From Emil Audero flare scandal as Cremonese lose to Inter Milan, Luciano Spalletti working wonders at Juventus where Weston McKennie and Jonathan David shine, Antonio Vergara shines for Napoli who win but lose Giovanni Di Lorenzo to injury, Serie B looms for Fiorentina, Marco Carnesecchi heroics for Atalanta in goalless draw with Como, to Lazio beat Genoa in 5 goal thriller, Cagliari smash Hellas Verona, and Domenico Berardi brace for Sassuolo ends Alberto Gilardino era at Pisa, as well as this week's Baggio, Serie ASS and Premface of the week plus much, much more when Nima and Carlo break down all the main talking points from Match Day 23 of the 2025/2026 Serie A season. Timestamps: 00:00 Intro - Match Day 23 Episode Overview 01:54 Cremonese - Emil Audero Flare Scandal & Why Game Not Postponed 09:18 Inter Milan - Lautaro Martinez Equals Alessandro Altobelli Serie A Goal Record 15:07 Juventus - Luciano Spalletti Outstanding: Weston Mckennie & Jonathan David Shine 29:46 Napoli - Costly Win As Antonio Vergara Shines & Giovanni Di Lorenzo Suffers Injury 52:53 Fiorentina - Roberto Piccoli Did Well As Serie B Looming After Yet Another Loss 54:16 Como - Dominate But Marco Carnesecchi Saves Atalanta With Miracle Performance 01:06:17 Best Of The Rest - Lazio Win 5 Game Thriller Over Genoa, Domenico Berardi Brace As Sassuolo End Alberto Gilardino Era At Pisa, Semih Kılıçsoy Scores Stunner As Cagliari Smash Hellas Verona & Che Adams Torino Hero Against Lecce 01:10:13 Transfer Deadline Day - AC Milan Sign Alphadjo Cissé, Ademola Lookman To Atletico Madrid & Much More 01:17:35 January Transfer Window - The Winners & Losers Of The Winter Mercato 01:23:44 Baggio, Premface & Serie ASS Of The Week - Carnesecchi Heroics, Referee Vergara Gaffe, Serie A Raspadori Owngoal & Daniel + Paolo Maldini Mixup as well as Jeffrey Epstein "Not Interested" In Buying Milan If you want to support The Italian Football Podcast and get every episode, simply become a member on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon.com/TIFP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ OR ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ OR ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Memberships⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Your support makes The Italian Football Podcast possible.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok Learn more about your ad choices. Visit podcastchoices.com/adchoices

Vittorio and Alasdair review an eventful week where Lazio defeated Genoa 3-2 in an almost empty Stadio Olimpico. We discuss the stadium boycott and where the anti-Lotito protests will go from here, Alessio Romagnoli's future and if Nuno Tavares and Pedro could still make an impact this season Hosted on Acast. See acast.com/privacy for more information.

Mariah kidnaps Dom. Abby & Devon terrified; Tessa identifies Mariah’s scarf; The Newmans plan an abduction ruse; Phyllis fights with Victoria, then loses Summer and Sharon; Jill’s condition worsens and Billy keeps Chancellor reveal from her; and Harrison plays matchmaker for Kyle and Claire! Visit https://www.yrchat.com to chat with fun and friendly fans of The […]

In this special edition of BOAT Briefing Caroline White and Cecile Gauert project themselves to a cool evening in Kitzbühel, Austria, when the winners collected their beautiful Minervas at the 2026 BOAT Design & Innovation Awards ceremony. The two go through all the winners and categories, and reveal some of the thought process involved in the judges' choices to select winners among a strong field of finalists.This episode of BOAT Briefing is sponsored by Amico & Co, a Genoa-based, family-owned refit yard with more than 200 years of maritime heritage, renowned for its full-service refit expertise on large yachts, delivered through highly specialised in-house teams.BOATPro: https://boatint.com/3qw Subscribe: https://boatint.com/3qx Contact us: podcast@boatinternationalmedia.com

Shawn and Caleb give their immediate reactions and analysis to Lazio's 3-2 win over Genoa. Learn more about your ad choices. Visit megaphone.fm/adchoices

Amorim, revelado na base do Fortaleza, foi vendido pelo Alverca ao Genoa. Como o clube cearense ainda detinha direitos econômicos do jogador, a transferência deve render mais de R$ 17 milhões ao FEC. Mesmo fora de campo, o atacante pode virar um reforço financeiro decisivo para o planejamento do Fortaleza em 2026. Nos comentários do […]

"A MAN WHO IS FREE NEVER DIES!"Marten begins his journey through the annals of Italian exploitation cinema, with Jacob giggling along for the ride. His first stop: the violent, entertaining, marinara genre collaborations between Enzo Castellari and Franco Nero, including the acid trip spaghetti Western, KEOMA. Pick up a six-shooter and throw a tab on your tongue, we're going to Genoa!

As urban areas continue to grow and evolve, the safety and reliability of critical infrastructure such as bridges, tunnels, and highways have become paramount concerns. Luca Cornali from AIDA INNOVAZIONE sheds light on the pressing issue of aging infrastructure and the innovative solutions being developed to monitor and maintain these vital structures. He explores the importance of monitoring aging infrastructure, the challenges posed by deterioration, and the potential for technology to enhance public safety.The State of Aging InfrastructureMany of the bridges and tunnels that form the backbone of transportation networks were constructed during the economic boom of the mid-20th century. These structures, built to withstand the demands of a different era, are now facing significant challenges due to age, increased traffic, and the impacts of climate change. The tragic collapse of the Morandi Bridge in Genoa, Italy, serves as a stark reminder of the dangers posed by failing infrastructure. Similar incidents, like the I-35W Mississippi River bridge collapse in Minneapolis, highlight the urgent need for effective monitoring and maintenance strategies to ensure public safety.The aging infrastructure crisis is not limited to Italy or the United States; it is a global issue. As populations grow and urban areas expand, the demand on existing infrastructure increases, exacerbating the risks associated with aging structures. In this context, monitoring the health of these infrastructures is crucial to prevent catastrophic failures that can result in loss of life, economic disruption, and public distrust in governmental capabilities.The Role of Technology in MonitoringAIDA INNOVAZIONE offers a compelling solution to the infrastructure crisis through the development of a platform designed to monitor the health of critical infrastructure. By utilizing advanced sensors and IoT (Internet of Things) technology, AIDA INNOVAZIONE aims to provide real-time data on the condition of bridges and tunnels. This data can be invaluable for asset managers and government entities, enabling them to make informed decisions about maintenance and repairs before issues escalate into dangerous situations.Currently, AIDA INNOVAZIONE's platform operates primarily on a business-to-business model, focusing on partnerships with government agencies and private companies responsible for infrastructure management. However, the vision for the future includes a more interconnected system where vehicles and infrastructure communicate directly. This "vehicle-to-everything" (V2X) approach could revolutionize how we interact with our built environment, allowing for proactive measures to be taken in response to potential hazards.Engaging the PublicWhile the current model primarily serves government and corporate entities, there is a growing recognition of the need to engage the public in infrastructure monitoring. Citizens often have firsthand experience with the conditions of local bridges and roads and can provide valuable insights into their safety. As technology evolves, there is potential for platforms like AIDA INNOVAZIONE's to incorporate public feedback mechanisms, allowing individuals to report concerns or observations about infrastructure conditions directly.This engagement could foster a sense of community responsibility and awareness regarding infrastructure safety. It could also enhance the effectiveness of monitoring systems by providing a more comprehensive view of the conditions that may not be captured by sensors alone.Future ProspectsLooking ahead, the integration of monitoring technologies with public engagement represents a promising avenue for improving infrastructure safety. As Luca Cornali suggests, the future may see a seamless interaction between vehicles and infrastructure, where real-time data exchange can prevent accidents and enhance safety measures. This vision underscores the importance of investing in innovative monitoring solutions and fostering collaboration between public agencies, private companies, and citizens.ConclusionIn conclusion, monitoring aging infrastructure is a critical component of ensuring public safety in our increasingly urbanized world. Through advanced technology and collaborative efforts, AIDA INNOVAZIONE can help address the challenges posed by deteriorating structures and create a safer environment for all. As we look to the future, it is essential to prioritize infrastructure health and safety, leveraging innovation to protect communities and enhance quality of life.Interview by Scott Ertz of PLUGHITZ Live.Sponsored by: Get $5 to protect your credit card information online with Privacy. Amazon Prime gives you more than just free shipping. Get free music, TV shows, movies, videogames and more. Secure your connection and unlock a faster, safer internet by signing up for PureVPN today.

In conversation with BOAT International's online editor Holly Margerrison, Fraser's CEO Anders Kurtén reflects on nearly three years at the helm of one of the superyacht industry's most established brokerages. The discussion spans brokerage and charter performance, shifting client demographics, the rise of far-flung destinations, sustainability and transparency – and what the data is revealing about where the market is heading next.This episode of BOAT Briefing is sponsored by Amico & Co, a Genoa-based, family-owned refit yard with more than 200 years of maritime heritage, renowned for its full-service refit expertise on large yachts, delivered through highly specialised in-house teams.BOATPro: https://boatint.com/3m0Subscribe: https://boatint.com/3m1Contact us: podcast@boatinternationalmedia.com

Gestora, que tem aproximadamente R$ 18 bilhões sob gestão, gosta de teses resilientes no Brasil e está “comprada” em inovação no exterior. José Luiz Torres, sócio da Genoa Capital, explica o movimento neste episódio do Café com Investidor

Is Mariah going to kidnap Dominic?; Sally and Billy argue over Cane’s Chancellor offer; Victoria confronts Cane and Phyllis; Adam and Chelsea togetherness; Victor catches Jack and Nikki in a hug embrace; Matt Clark becomes Victor’s punching bag; and Nick on drugs. Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and […]

Is Nick going to murder Matt?; Phyllis and Cane take over Newman Enterprises; Nick confronts Phyllis; Cane offers Chancellor to Billy, and Sally argues against it; and Tessa tells Sharon she’s divorcing Mariah. Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. THIS WEEK: Ali’s Y&R Recap, The Weekly […]

EXCLUSIVE NordVPN Deal ➼ https://nordvpn.com/efc Try it risk-free now with a 30-day money-back guarantee Host Ian Croll is joined by Chris Beesley and Joe Thomas on the Royal Blue podcast to unpack the latest transfer talk around potential incomings at Hill Dickinson Stadium. The panel assess reported links to Fenerbahçe and Morocco international striker Youssef En‑Nesyri — addressing Everton's urgent need for quality up front — and discuss a possible move for Genoa right-back Brooke Norton‑Cuffy. Attention then turns to on‑pitch matters as the Blues travel to Birmingham on Sunday evening to face Aston Villa, aiming to bounce back after a torrid week of results. Get involved in the comments and subscribe for more Everton updates. Chris Beesley's Book: Spirit of the Blues: https://tinyurl.com/35yrkvdb *Emotional farewell to Goodison Park | 16-page Everton souvenir picture special:*  https://shop.regionalnewspapers.co.uk/liverpool-echo-monday-19th-may-2025-4583-p.asp *Goodbye to Goodison special souvenir edition:*  https://tinyurl.com/GoodbyeGoodisonSouvenir *Gavin Buckland's Book 'The End' | Order your copy here:* https://tinyurl.com/GavinBucklandTheEnd Everton FC podcasts from the Liverpool ECHO's Royal Blue YouTube channel. Get exclusive Everton FC content - including podcasts, live shows and videos - everyday.  Subscribe to the Royal Blue Everton FC YouTube Channel and watch daily live shows HERE: https://bit.ly/3aNfYav Listen and subscribe to the Royal Blue Podcast for all your latest Everton FC content via Apple and Spotify: APPLE: https://bit.ly/3HbiY1E SPOTIFY: https://bit.ly/47xwdnY Visit the Liverpool ECHO website: https://www.liverpoolecho.co.uk/all-about/everton-fc Follow us on Twitter: https://twitter.com/LivEchoEFC Follow us on TikTok: https://www.tiktok.com/@royal.blue.evertoFollow us on Facebook: https://www.facebook.com/LiverpoolEchoEFC Learn more about your ad choices. Visit podcastchoices.com/adchoices

In the first BOAT Briefing podcast of the year, online editor Holly Margerrison and business editor Gabrielle Lazaridis kick off 2026 by taking stock of the market's early signals. From counting the superyachts spotted in St Barths and what that activity reveals about the charter landscape, to looking ahead at the most anticipated yacht deliveries due to hit the water in 2026, the duo unpack what's coming next. They also reflect on the biggest business stories of 2025, revisit BOAT International's most-read yacht reports of the year and share their personal new year's resolutions for the months ahead.This episode of BOAT Briefing is sponsored by Amico & Co, a Genoa-based, family-owned refit yard with more than 200 years of maritime heritage, renowned for its full-service refit expertise on large yachts, delivered through highly specialised in-house teams.Episode links:https://www.boatinternational.com/yachts/news/superyachts-sightings-in-st-barths-new-years-eve-2026https://www.boatinternational.com/yachts/news/biggest-upcoming-superyacht-deliveries-2026https://www.boatinternational.com/boat-pro/news/biggest-yachting-business-news-stories-2025https://www.boatinternational.com/yachts/editorial-features/exclusive-new-yachts-superyachts-2025-m…

On May 29th, 1453, Constantinople fell—and with it, the last continuation of Rome.But the real story isn't just Ottoman cannons and overwhelming numbers.It's the cold mathematics of power: betrayal, sabotage, and profit-driven neutrality.In this episode of Hidden Forces in History, we follow the receipts behind one of the most pivotal days in world history:why the city was still defensible (if help had come)how Genoa's colony of Galata stayed “neutral” while Ottoman ships passedwhy Venice negotiated safe passage instead of fightinghow Western Europe sent prayers instead of armiesand why the fall wasn't inevitable—it was a series of choicesBecause the most disturbing truth is this:Constantinople didn't fall because it was weak. It fell because powerful allies decided it was convenient to let it fall.If you want history as investigation—documents, incentives, and the people who benefited—subscribe for weekly deep dives into the hidden forces behind the official story.Question for you: Was this “inevitable”… or a calculated sacrifice?

Matt Clark captured, freed, then captured again; The Abbotts propose a trade with Victor; Cane and Phyllis plan a NE takeover; Michael and Nikki team up; Tessa and Sienna are old friends; and Audra makes nice with Holden and Claire. Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. […]

Slavery did not end in the nineteenth century—it persists today, hidden in global supply chains, religious justifications, and systems of power. Kevin Bales and Michael Rota join Evan Rosa to explore modern slavery through history, psychology, and theology, asking why it remains so difficult to see and confront.“It's time some person should see these calamities to their end.” (Thomas Clarkson, 1785)“There are millions of slaves in the world today.” (Kevin Bales, 2025)In this episode, they consider how conscience, power, and religious belief can either sustain enslavement or become forces for abolition. Together they discuss the psychology of slaveholding, faith's complicity and resistance, Quaker abolitionism, modern debt bondage, ISIS and Yazidi slavery, and what meaningful action looks like today.https://freetheslaves.net/––––––––––––––––––Episode Highlights“There are millions of slaves in the world today.”“Statistics isn't gonna do it. I need to actually show people things.”“They have sexual control. They can do what they like.”“Slavery is flowing into our lives hidden in the things we buy.”“We have to widen our sphere of concern.”––––––––––––––––––About Kevin BalesKevin Bales is a leading scholar and activist in the global fight against modern slavery. He is Professor of Contemporary Slavery at the University of Nottingham and co-founder of Free the Slaves, an international NGO dedicated to ending slavery worldwide. Bales has spent more than three decades researching forced labor, debt bondage, and human trafficking, combining academic rigor with on-the-ground investigation. His work has shaped international policy, influenced anti-slavery legislation, and brought global attention to forms of enslavement often dismissed as historical. He is the author of several influential books, including Disposable People and Friends of God, Slaves of Men, which examines the complex relationship between religion and slavery across history and into the present. Learn more and follow at https://www.kevinbales.org and https://www.freetheslaves.netAbout Michael RotaMichael Rota is Professor of Philosophy at the University of St. Thomas in Minnesota, where he teaches and researches in the philosophy of religion, moral psychology, and the history of slavery and religion. His work spans scholarly articles on the definition of slavery, the moral psychology underlying social change and abolition, and the relevance of theological concepts to ethical life. Rota is co-author with Kevin Bales of Friends of God, Slaves of Men: Religion and Slavery, Past and Present, a comprehensive interdisciplinary study of how religions have both justified and resisted systems of enslaving human beings from antiquity to the present day. He is also the author of Taking Pascal's Wager: Faith, Evidence, and the Abundant Life, an extended argument for the reasonableness and desirability of Christian commitment. In addition to his academic writing, he co-leads projects in philosophy and education and is co-founder of Personify, a platform exploring AI and student learning. Learn more and follow at his faculty profile and personal website https://mikerota.wordpress.com and on X/Twitter @mikerota.––––––––––––––––––Helpful Links And ResourcesDisposable People by Kevin Baleshttps://www.ucpress.edu/book/9780520281820/disposable-peopleFriends of God, Slaves of Men by Kevin Bales and Michael Rotahttps://www.ucpress.edu/book/9780520383265/friends-of-god-slaves-of-menFree the Slaveshttps://www.freetheslaves.netVoices for Freedomhttps://voicesforfreedom.orgInternational Justice Missionhttps://www.ijm.orgTalitha Kumhttps://www.talithakum.info––––––––––––––––––Show Notes– Slavery named as a contemporary moral crisis obscured by twentieth-century abolition narratives– Kevin Bales's encounter with anti-slavery leaflet in London, mid-1990s– “There are millions of slaves in the world today … I thought, look, that can't be true because I don't know that. I'm a professor. I should know that.”– Stories disrupting moral distance more powerfully than statistics– “There were three little stories inside, about three different types of enslavement … it put a hook in me like a fish and pulled me.”– United Nations documentation mostly ignored despite vast evidence– Decades of investigation into contemporary slavery– Fieldwork across five regions, five forms of enslavement– Kevin Bales's book, Disposable People as embodied witness with concrete stories– “Statistics isn't gonna do it. I need to actually show people things. There's gonna be something that breaks hearts the way it did me when I was in the field.”– Psychological resistance to believing slavery touches ordinary life– Anti-Slavery International as original human rights organization founded in U.K. in 1839– Quaker and Anglican foundations of abolitionist movements– Religion as both justification for slavery and engine of resistance– Call for renewed faith-based abolition today– Slavery and religion intertwined from early human cultures– Colonial expansion intensifying moral ambiguity– Columbus, Genoa, and enslavement following failed gold extraction– Spanish royal hesitation over legitimacy of slavery– Las Casas's moral conversion after refusal of absolution– “He eventually realized this is totally wrong. What we are doing, we are destroying these people. And this is not what God wants us to be doing.”– Sepúlveda's Aristotelian defense of hierarchy and profit– Moral debate without effective structural enforcement– Power described as intoxicating and deforming conscience– Hereditary debt bondage in Indian villages– Caste, ethnicity, and generational domination– Sexual violence as mechanism of absolute control– “They have sexual control. They can beat up the men, rape the women, steal the children. They can do pretty much what they like.”– Three-year liberation process rooted in trust, education, and collective refusal– Former slaves returning as teachers and organizers– Liberation compared to Plato's allegory of the cave– Post-liberation vulnerability and risk of recapture– Power inverted in Christian teaching– “The disciples are arguing about who's the greatest, and Jesus says, the greatest among you will be the slave of all… don't use power to help yourself. Use it to serve.”– Psychological explanations for delayed abolition– The psychological phenomenon of “motivated reasoning” that shapes moral conclusions– “The conclusions we reach aren't just shaped by the objective evidence the world provides. They're shaped also by the internal desires and goals and motivations people have.”– Economic self-interest and social consensus sustaining injustice– Quaker abolition through relational, conscience-driven confrontation– First major religious body to forbid slaveholding– Boycotts of slave-produced goods and naval blockade of slave trade– Modern slavery as organized criminal enterprise– ISIS enslavement of Yazidi women– Religious reasoning weaponized for genocide– “They said, for religious reasons, we just need to eradicate this entire outfit.”– Online slave auctions and cultural eradication– Internal Islamic arguments for abolition– Restricting the permissible for the common good– Informing conscience as first step toward action– Community sustaining long-term resistance– Catholic religious sisters as leading global abolitionists– Hidden slavery embedded in everyday consumer goods– “There's so much slavery flowing into our lives which is hidden… in our homes, our watches, our computers, the minerals, all this.”– Expanding moral imagination beyond immediate needs– “Your sphere of concern has to be wider… how do I start caring about something that I don't see?”– “It's time some person should see these calamities to their end.” (Thomas Clarkson, 1785)––––––––––––––––––#ModernSlavery#FaithAndJustice#HumanDignity#Abolition#FreeTheSlavesProduction NotesThis podcast featured Kevin Bales and Michael RotaEdited and Produced by Evan RosaHosted by Evan RosaProduction Assistance by Noah SenthilA Production of the Yale Center for Faith & Culture at Yale Divinity School https://faith.yale.edu/aboutSupport For the Life of the World podcast by giving to the Yale Center for Faith & Culture: https://faith.yale.edu/give